268 related articles for article (PubMed ID: 28700487)
21. Association of glutathione-S-transferase p1 gene promoter methylation and the incidence of prostate cancer: a systematic review and meta-analysis.
Zhou X; Jiao D; Dou M; Chen J; Li Z; Li Y; Liu J; Han X
J Cancer Res Clin Oncol; 2019 Aug; 145(8):1939-1948. PubMed ID: 31263949
[TBL] [Abstract][Full Text] [Related]
22. Promoter methylation of BRCA1 in the prognosis of breast cancer: a meta-analysis.
Wu L; Wang F; Xu R; Zhang S; Peng X; Feng Y; Wang J; Lu C
Breast Cancer Res Treat; 2013 Dec; 142(3):619-27. PubMed ID: 24258259
[TBL] [Abstract][Full Text] [Related]
23. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients.
Sharma G; Mirza S; Parshad R; Srivastava A; Gupta SD; Pandya P; Ralhan R
Life Sci; 2010 Jul; 87(3-4):83-91. PubMed ID: 20470789
[TBL] [Abstract][Full Text] [Related]
24. Methylated DNA and total DNA in serum detected by one-step methylation-specific PCR is predictive of poor prognosis for breast cancer patients.
Fujita N; Nakayama T; Yamamoto N; Kim SJ; Shimazu K; Shimomura A; Maruyama N; Morimoto K; Tamaki Y; Noguchi S
Oncology; 2012; 83(5):273-82. PubMed ID: 22964822
[TBL] [Abstract][Full Text] [Related]
25. Region-specific glucocorticoid receptor promoter methylation has both positive and negative prognostic value in patients with estrogen receptor-positive breast cancer.
Snider H; Villavarajan B; Peng Y; Shepherd LE; Robinson AC; Mueller CR
Clin Epigenetics; 2019 Nov; 11(1):155. PubMed ID: 31675993
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Effects of RASSF1A, BRCA1, APC, and p16 Promoter Methylation in Ovarian Cancer: A Meta-Analysis.
Chen C; Zhu Y; Zhang H; Xiao L
Gynecol Obstet Invest; 2024 Apr; ():1-13. PubMed ID: 38615670
[TBL] [Abstract][Full Text] [Related]
27. BRCA1 promoter methylation of normal breast epithelial cells as a possible precursor for BRCA1-methylated breast cancer.
Otani Y; Miyake T; Kagara N; Shimoda M; Naoi Y; Maruyama N; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Cancer Sci; 2014 Oct; 105(10):1369-76. PubMed ID: 25155055
[TBL] [Abstract][Full Text] [Related]
28. The Prognostic Value of p16 Hypermethylation in Cancer: A Meta-Analysis.
Xing XB; Cai WB; Luo L; Liu LS; Shi HJ; Chen MH
PLoS One; 2013; 8(6):e66587. PubMed ID: 23805242
[TBL] [Abstract][Full Text] [Related]
29. Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma.
Sailer V; Gevensleben H; Dietrich J; Goltz D; Kristiansen G; Bootz F; Dietrich D
PLoS One; 2017; 12(6):e0179412. PubMed ID: 28617833
[TBL] [Abstract][Full Text] [Related]
30. Hypermethylation of the GSTP1 promoter region in breast cancer is associated with prognostic clinicopathological parameters.
Lasabova Z; Tilandyova P; Kajo K; Zubor P; Burjanivova T; Danko J; Plank L
Neoplasma; 2010; 57(1):35-40. PubMed ID: 19895170
[TBL] [Abstract][Full Text] [Related]
31. Multicenter study using paraffin-embedded tumor tissue testing PITX2 DNA methylation as a marker for outcome prediction in tamoxifen-treated, node-negative breast cancer patients.
Harbeck N; Nimmrich I; Hartmann A; Ross JS; Cufer T; Grützmann R; Kristiansen G; Paradiso A; Hartmann O; Margossian A; Martens J; Schwope I; Lukas A; Müller V; Milde-Langosch K; Nährig J; Foekens J; Maier S; Schmitt M; Lesche R
J Clin Oncol; 2008 Nov; 26(31):5036-42. PubMed ID: 18711169
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer.
Ramos EA; Camargo AA; Braun K; Slowik R; Cavalli IJ; Ribeiro EM; Pedrosa Fde O; de Souza EM; Costa FF; Klassen G
BMC Cancer; 2010 Jan; 10():23. PubMed ID: 20109227
[TBL] [Abstract][Full Text] [Related]
33. Gene promoter hypermethylation in tumors and lymph nodes of stage I lung cancer patients.
Harden SV; Tokumaru Y; Westra WH; Goodman S; Ahrendt SA; Yang SC; Sidransky D
Clin Cancer Res; 2003 Apr; 9(4):1370-5. PubMed ID: 12684406
[TBL] [Abstract][Full Text] [Related]
34. The prognostic value of epigenetic silencing of p16 gene in NSCLC patients: a systematic review and meta-analysis.
Lou-Qian Z; Rong Y; Ming L; Xin Y; Feng J; Lin X
PLoS One; 2013; 8(1):e54970. PubMed ID: 23372805
[TBL] [Abstract][Full Text] [Related]
35. ESR1-promoter-methylation status in primary breast cancer and its corresponding metastases.
Kirn V; Strake L; Thangarajah F; Richters L; Eischeid H; Koitzsch U; Odenthal M; Fries J
Clin Exp Metastasis; 2018 Oct; 35(7):707-712. PubMed ID: 30173322
[TBL] [Abstract][Full Text] [Related]
36. Hypermethylated 14-3-3-sigma and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis.
Zurita M; Lara PC; del Moral R; Torres B; Linares-Fernández JL; Arrabal SR; Martínez-Galán J; Oliver FJ; Ruiz de Almodóvar JM
BMC Cancer; 2010 May; 10():217. PubMed ID: 20487521
[TBL] [Abstract][Full Text] [Related]
37. DNA hypermethylation of ESR1 and PGR in breast cancer: pathologic and epidemiologic associations.
Gaudet MM; Campan M; Figueroa JD; Yang XR; Lissowska J; Peplonska B; Brinton LA; Rimm DL; Laird PW; Garcia-Closas M; Sherman ME
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3036-43. PubMed ID: 19861523
[TBL] [Abstract][Full Text] [Related]
38. Exploring DNA methylation changes in promoter, intragenic, and intergenic regions as early and late events in breast cancer formation.
Rauscher GH; Kresovich JK; Poulin M; Yan L; Macias V; Mahmoud AM; Al-Alem U; Kajdacsy-Balla A; Wiley EL; Tonetti D; Ehrlich M
BMC Cancer; 2015 Oct; 15():816. PubMed ID: 26510686
[TBL] [Abstract][Full Text] [Related]
39. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma.
Kwong J; Lo KW; To KF; Teo PM; Johnson PJ; Huang DP
Clin Cancer Res; 2002 Jan; 8(1):131-7. PubMed ID: 11801549
[TBL] [Abstract][Full Text] [Related]
40. Clinical and prognostic effects of
Xia L; Zhang W; Gao L
Biomarkers; 2019 Nov; 24(7):700-711. PubMed ID: 31382782
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
